Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT04619602 Suspended - Clinical trials for Bronchopulmonary Dysplasia

Inhaled Treatment for Bronchopulmonary Dysplasia

Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of bronchopulmonary dysplasia

NCT ID: NCT04607252 Terminated - Clinical trials for Atypical Endometrial Hyperplasia

Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia

Start date: January 11, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).

NCT ID: NCT04591067 Completed - Clinical trials for Musculoskeletal Diseases

Physical Capacity Among Patients Treated With Periacetabular Osteotomy for Hip Dysplasia: a Cross-sectional Study

Start date: June 1, 2020
Phase:
Study type: Observational

This cross-sectional study investigates the physical capacity of patients, who have undergone a periacetabular osteotomy for hip dysplasia within the last 1-5 years.

NCT ID: NCT04590534 Recruiting - Clinical trials for Prostatic Hyperplasia

Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH

BPH
Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of garcinia extract + chromium combinations (Chromax) in symptomatic benign prostatic hypertrophy patients

NCT ID: NCT04588857 Recruiting - Clinical trials for Prostatic Hyperplasia

Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms (LUTS) in men. One fourth of men older than 70 have moderate to severe LUTS that impair their quality of life (QOL). Prostatic artery embolization (PAE) is a new minimally invasive technique proven effective in reducing LUTS comparable to the mainstay treatment - the transurethral resection of the prostate (TURP). The most common side effect of PAE is a collection of inflammation-related symptoms known as the postembolization syndrome (PES). The symptoms include pelvic pain, fever, nausea, and transient worsening of LUTS (painful and difficult urination). PES is a self-limiting condition that is treated symptomatically with painkillers and antipyretics. However, PES can be so severe that the patients experience high fever, shivers, dysuria and urgency mimicking a septicemia from the urinary tract. It is a clinical challenge to avoid exposure to unnecessary antibiotics treatment in those situations. A subset of patients may need admission to the hospital for observation, especially in case of fever. Usually, PES resolves within a week after PAE. Steroids have been successfully used to reduce the incidence and severity of PES after a number of procedures in interventional radiology. The investigators postulate that steroids can have a similar effect in reducing PES after PAE. In this study, the efficacy of single high dose postprocedural dexamethasone (DEXA) administration in reducing PES after PAE will be evaluated, compared to placebo.

NCT ID: NCT04580628 Completed - Clinical trials for Prostate Hyperplasia

Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)

Start date: July 1, 2020
Phase:
Study type: Observational

Thuflep TLF: initial experience and results of prostate laser enucleation with fibrous thulium laser (TLF)

NCT ID: NCT04579913 Terminated - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A Multi-center, International Prospective Follow up Study

Start date: December 21, 2020
Phase:
Study type: Observational

The study objective is to assess the safety and efficacy of iTind three to five years following treatment.

NCT ID: NCT04577040 Not yet recruiting - Clinical trials for Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia

Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia

Start date: October 1, 2020
Phase:
Study type: Observational

To study Safety and efficacy of Tadalafil vs. Tadalafil with Sildosin in the management of moderately and severely symptomatic patients of prostatic hyperplasia

NCT ID: NCT04576104 Recruiting - Clinical trials for Endometrial Carcinoma

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Start date: November 29, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestrol acetate together may decrease the growth of endometrial intraepithelial neoplasia in the uterus better than megestrol alone.

NCT ID: NCT04570956 Recruiting - Breast Carcinoma Clinical Trials

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Start date: July 26, 2021
Phase: Phase 2
Study type: Interventional

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).